01P Stock Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$365.10 |
| 52 Week High | US$386.20 |
| 52 Week Low | US$184.40 |
| Beta | 1.4 |
| 1 Month Change | -1.35% |
| 3 Month Change | 30.39% |
| 1 Year Change | 91.55% |
| 3 Year Change | 178.70% |
| 5 Year Change | 661.50% |
| Change since IPO | 1,310.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 01P | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.2% | -1.0% |
| 1Y | 91.6% | -14.1% | 2.2% |
Return vs Industry: 01P exceeded the German Life Sciences industry which returned -14.1% over the past year.
Return vs Market: 01P exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 01P volatility | |
|---|---|
| 01P Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 01P's share price has been volatile over the past 3 months.
Volatility Over Time: 01P's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 5,800 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| 01P fundamental statistics | |
|---|---|
| Market cap | €11.27b |
| Earnings (TTM) | €290.15m |
| Revenue (TTM) | €1.82b |
38.9x
P/E Ratio6.2x
P/S RatioIs 01P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 01P income statement (TTM) | |
|---|---|
| Revenue | US$1.96b |
| Cost of Revenue | US$658.67m |
| Gross Profit | US$1.30b |
| Other Expenses | US$991.82m |
| Earnings | US$312.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.10 |
| Gross Margin | 66.44% |
| Net Profit Margin | 15.91% |
| Debt/Equity Ratio | 0% |
How did 01P perform over the long term?
See historical performance and comparison